FDA Validates the Role of Switching Studies

🚨 Big news from FDA!

The authorization of JUUL's tobacco and menthol-flavored e-cigarette products is not just a regulatory milestone — it’s a validation of something our team at ARAC has long championed: the critical role of SWITCHING STUDIES in demonstrating population-level benefit.

As FDA noted in their press release, the law requires consideration of whether a product provides “benefits to adults who currently smoke cigarettes and completely switch to a potentially less harmful product or significantly reduce their cigarette use.”

We’re thrilled to see this principle in action — and proud that our research approach has consistently aligned with this public health mandate. Switching studies are not optional. They are central to assessing how these products perform in the real world, and how they can contribute to meaningful harm reduction.

Kudos to all involved in this rigorous application and review.

🔗 https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-marketing-tobacco-and-menthol-flavored-juul-e-cigarette-products